Peritoneal Cancer
MK5909-003: A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants with High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy
- Details
ClinicalTrials.gov ID:
NCT06843447
Diagnosis Type:
NA
USOR Number:
- Address
,
P: